Radioimmunotherapy in colorectal cancer treatment: present and future
Authors:
Open Access
- 10 May 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14
Abstract
Colorectal cancer (CRC) is a deadly form of cancer worldwide. Patients with locally advanced rectal cancer and metastatic CRC have a poor long-term prognosis, and rational and effective treatment remains a major challenge. Common treatments include multi-modal combinations of surgery, radiotherapy, and chemotherapy; however, recurrence and metastasis rates remain high. The combination of radiotherapy and immunotherapy (radioimmunotherapy [RIT]) may offer new solutions to this problem, but its prospects remain uncertain. This review aimed to summarize the current applications of radiotherapy and immunotherapy, elaborate on the underlying mechanisms, and systematically review the preliminary results of RIT-related clinical trials for CRC. Studies have identified several key predictors of RIT efficacy. Summarily, rational RIT regimens can improve the outcomes of some patients with CRC, but current study designs have limitations. Further studies on RIT should focus on including larger sample sizes and optimizing the combination therapy regimen based on underlying influencing factors.Keywords
Funding Information
- National Natural Science Foundation of China
This publication has 80 references indexed in Scilit:
- Non-surgical interventions for late rectal problems (proctopathy) of radiotherapy in people who have received radiotherapy to the pelvisCochrane Database of Systematic Reviews, 2016
- Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent CellsRadiation Research, 2016
- Microsatellite Instability as a Biomarker for PD-1 BlockadeClinical Cancer Research, 2016
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic TumorsImmunity, 2014
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 BlockadeCancer Research, 2014
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 AntibodyClinical Cancer Research, 2009
- Radioimmunotherapy of B-cell non-Hodgkin's lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Distribution of radiation sensitivities for human tumor cells of specific histological types: Comparison of in vitro to in vivo dataInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1986
- Whole Body Irradiation—Radiobiology or Medicine?British Journal of Radiology, 1953